 |
 |
 |
||
 |
March 2, 2009 |  |
||
 |
 |
|||
 |
Sound Science: The Severe Consequences of Sepsis Listen to Sound Science as pulmonologists Greg Martin and Annette Esper discuss sepsis, an overwhelming and potentially deadly immune response to infection. The Emory physician/ scientists are studying particular diseases and how they may affect the development of severe sepsis, septic shock and organ dysfunction in sepsis. Read and listen. . . |
|||
|
|
|||
 |
How Biology Influences Our Economic Choices The emotional relationship to money and other things we value is rooted in our biology. Scientists are delving deeper into the wiring that influences the choices we make related to risk and reward, greed and altruism, and cooperation and self-interest. Read more. . . |
|||
|
|
|||
 Electron microscopy of pandemic influenza H5N1 VLPs |
Virus-Like Particles May Offer Solution to Avian Flu Vaccines Vaccines against H5N1 influenza will be critical in countering a future flu pandemic, yet the current method of growing flu vaccines in chicken eggs is slow and inefficient. Emory Vaccine Center scientists have developed virus-like particles (VLPs) that look like viruses but don't reproduce. Mice immunized by nose drops with the VLPs were protected for months against a lethal H5N1 infection. Read more. . . |
|||
|
|
|||
 Brain scan showing glioblastoma |
Naturally Occurring Protein Can Shrink Brain Tumors' Blood Supply Vasculostatin, a piece of a protein found in the brain, can stop tumors in rats' brains from growing new blood vessels. Since tumors need to expand their blood supply in order to grow, the protein fragment could act as a potent blocker of tumor growth. Read more. . . |
|||
|
|
|||
Emory Ranks 16th Nationally in Licensing Revenue from Research Discoveries The Association of University Technology Managers (AUTM) ranks Emory 16th in revenue from commercializing research discoveries. The funds include royalties from licensed drugs, diagnostics, devices and consumer products. Emory's Office of Technology Transfer had 40 new licensing deals in 2007 and 24 in 2008, and launched nine new companies in those two years. Read more. . . |
||||
 |
 |
|||
